XML 269 R37.htm IDEA: XBRL DOCUMENT
v3.23.1

Intangible Assets (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Reconciliation of the Activity Affecting Intangible Assets | A reconciliation of the activity affecting intangible assets, net for each of 2023 and 2022 is as follows:
| Year Ended March 31, 2023
(In thousands) | Indefinite- Lived Tradenames |  | Finite-Lived Tradenames and Customer Relationships |  | Totals
Gross Carrying Amounts |  |  |  |  |
Balance – March 31, 2022 | $ | 2,476,559 |  |  | $ | 436,174 |  |  | $ | 2,912,733 |
Tradename impairment | (298,664) |  |  | (22,748) |  |  | (321,412) |
Effects of foreign currency exchange rates | (8,993) |  |  | (2,308) |  |  | (11,301) |
Balance – March 31, 2023 | $ | 2,168,902 |  |  | $ | 411,118 |  |  | $ | 2,580,020 |
Accumulated Amortization |  |  |  |  |
Balance – March 31, 2022 | $ | — |  |  | $ | 216,098 |  |  | $ | 216,098 |
Additions | — |  |  | 22,266 |  |  | 22,266 |
Effects of foreign currency exchange rates | — |  |  | (237) |  |  | (237) |
Balance – March 31, 2023 | $ | — |  |  | $ | 238,127 |  |  | $ | 238,127 |
Intangible assets, net – March 31, 2023 | $ | 2,168,902 |  |  | $ | 172,991 |  |  | $ | 2,341,893 |
Intangible Assets, net by Reportable Segment: |  |  |  |  |
North American OTC Healthcare | $ | 2,092,852 |  |  | $ | 154,552 |  |  | $ | 2,247,404 |
International OTC Healthcare | 76,050 |  |  | 18,439 |  |  | 94,489 |
Intangible assets, net – March 31, 2023 | $ | 2,168,902 |  |  | $ | 172,991 |  |  | $ | 2,341,893 |
| Year Ended March 31, 2022
(In thousands) | Indefinite- Lived Tradenames |  | Finite-Lived Tradenames and Customer Relationships |  |  | Totals
Gross Carrying Amounts |  |  |  |  |  |
Balance – March 31, 2021 | $ | 2,281,988 |  |  | $ | 389,347 |  |  |  | $ | 2,671,335 |
Additions (a) | 195,900 |  |  | 47,642 |  |  |  | 243,542 |
Tradename impairment | — |  |  | (1,700) |  |  |  | (1,700) |
Effects of foreign currency exchange rates | (1,329) |  |  | 885 |  |  |  | (444) |
Balance – March 31, 2022 | $ | 2,476,559 |  |  | $ | 436,174 |  |  |  | $ | 2,912,733 |
Accumulated Amortization |  |  |  |  |  |
Balance – March 31, 2021 | $ | — |  |  | $ | 195,606 |  |  |  | $ | 195,606 |
Additions | — |  |  | 21,499 |  |  |  | 21,499 |
Tradename impairment | — |  |  | (983) |  |  |  | (983) |
Effects of foreign currency exchange rates | — |  |  | (24) |  |  |  | (24) |
Balance – March 31, 2022 | $ | — |  |  | $ | 216,098 |  |  |  | $ | 216,098 |
Intangible assets, net – March 31, 2022 | $ | 2,476,559 |  |  | $ | 220,076 |  |  |  | $ | 2,696,635 |
Intangible Assets, net by Reportable Segment: |  |  |  |  |  |
North American OTC Healthcare | $ | 2,391,517 |  |  | $ | 198,353 |  |  |  | $ | 2,589,870 |
International OTC Healthcare | 85,042 |  |  | 21,723 |  |  |  | 106,765 |
Intangible assets, net – March 31, 2022 | $ | 2,476,559 |  |  | $ | 220,076 |  |  |  | $ | 2,696,635 |
(a) On July 1, 2021, we completed the acquisition of certain assets from Akorn (see Note 2) and on December 15, 2021, our Australian subsidiary acquired the rights to the Zaditen brand in certain territories from Novartis Pharma AG. In connection with these acquisitions, we allocated $225.4 million to intangible assets for Akorn and $18.1 million for Zaditen.
Schedule of Expected Amortization Expense | At March 31, 2023, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):
(In thousands) |
Year Ending March 31, | Amount
2024 | $ | 19,784 |
2025 | 18,099 |
2026 | 16,149 |
2027 | 14,557 |
2028 | 12,221 |
Thereafter | 92,181 |
| $ | 172,991 |

X
- Definition Schedule of Intangible Assets [Table Text Block] + References No definition available. + Details
Name: | pbh_ScheduleOfIntangibleAssetsTableTextBlock
Namespace Prefix: | pbh_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration